Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Figure 4 | BMC Immunology

Figure 4

From: Elevated CXCL12 expression in the bone marrow of NOD mice is associated with altered T cell and stem cell trafficking and diabetes development

Figure 4

AMD3100 inhibits naive T cell accumulation in the bone marrow of NOD mice. Prediabetic NOD mice (15–16 weeks of age) were treated with PBS or AMD3100 (AMD) daily for 8 days. Two hr after the last AMD3100 injection, mice were analyzed by flow cytometry. A, Comparison of percentage of CD4 and CD8 T cells (mean ± SD) in the bone marrow of AMD3100 (n = 4) and PBS (n = 6) treated NOD mice. * p < 0.05. B, Comparison of CD44 versus CD45RB profiles of TCR+CD4+ cells from AMD3100 (n = 4) and PBS (n = 6) treated NOD mice. The numbers indicate percentages of cells in the gated areas. The percentages (mean ± SE) of CD45RBhi CD44lo naïve T cells are 47.3 ± 10.9 for PBS-treated mice and 24.8 ± 3.2 for AMD3100-treated mice (p < 0.01).

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us